免疫检查点抑制剂治疗脑肿瘤后假性进展的临床与影像学特征
本研究回顾性纳入2015至2023年在本机构接受免疫检查点抑制剂治疗的102例成人脑肿瘤患者,10例(9.8%)出现假性进展,其中4例有临床症状且经皮质类固醇治疗均预后良好。假性进展组基线肿瘤负荷更高(p=1.29×10⁻¹³)、PD-L1表达更高(p<0.001),中位无进展生存期和总生存期数值上更长但无显著差异。作者认为假性进展是ICIs常见并发症,临床症状不应自动排除假性进展。
要点
- 102例接受ICIs的成人脑肿瘤患者中10例(9.8%)出现假性进展。
- 4例(40%)假性进展患者有临床症状,皮质类固醇治疗均预后良好。
- 假性进展组基线肿瘤负荷及PD-L1表达均高于非假性进展组。
核心结论
- 假性进展是免疫检查点抑制剂治疗脑肿瘤的常见并发症,有症状病例也不应自动排除假性进展,每个病例均需全面评估。
- 高PD-L1表达和较大肿瘤负荷可能与假性进展相关,但需进一步研究确认。
研究设计与样本
- 回顾性研究,纳入2015年至2023年在本机构接受免疫检查点抑制剂治疗的成人脑肿瘤(原发性或继发性)患者,共102例符合条件。
- 假性进展定义为ICI启动后6个月内影像学恶化、随后未经治疗调整而稳定或改善;要求治疗前及治疗启动后6个月内各有一次脑磁共振成像扫描。
主要发现
- 102例中10例(9.8%)出现假性进展;4例(40%)有临床症状,均经皮质类固醇治疗预后良好。
- 假性进展组基线肿瘤负荷高于非假性进展组(p=1.29×10⁻¹³),PD-L1表达也高于非假性进展组(p<0.001)。
- 假性进展组中位无进展生存期和总生存期数值上更长,但无显著差异。
临床怎么用
- 作者认为临床功能受损不应自动排除假性进展,每个病例均需全面评估。
- 作者指出本研究4例有症状假性进展患者对iRANO标准提出挑战,该标准建议在有症状病例中排除假性进展诊断。
局限性
- 原文为回顾性研究。
- 作者指出高PD-L1表达和较大肿瘤负荷与假性进展的关联需进一步研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Immune checkpoint inhibitors (ICIs) are increasingly used in cancer treatment, resulting in the emergence of various immune-related adverse effects, including pseudoprogression (PsP). We sought to evaluate the characteristics of pseudoprogression in adults treated with ICIs for brain tumors (either primary or secondary), and to compare it with a non- PsP group. METHODS: We retrospectively identified adults with brain tumors treated with ICIs at our institution between 2015 and 2023. Eligibility required one brain magnetic resonance imaging scan prior to treatment and another obtained within 6 months after treatment initiation. PsP was defined as radiological worsening within 6 months of ICI initiation, followed by stabilization or improvement without therapy modification. Demographic, clinical, and radiological characteristics were analyzed and compared between the PsP and the non-PsP groups. RESULTS: Among 102 eligible patients, 10 (9.8%) developed PsP. Clinical symptoms occurred in 4 (40%) cases, all of which showed favorable outcomes with corticosteroid therapy. The PsP group had higher baseline tumor burden (p = 1.29 × 10⁻¹³) and higher PD-L1 expression (p < 0.001) than the non-PsP group. Median progression-free survival and overall survival were numerically longer in the PsP group with no significant difference. CONCLUSIONS: PsP is a frequent complication of ICIs. We describe 4 symptomatic patients with pseudoprogression, challenging the iRANO criteria that recommend excluding this diagnosis in symptomatic cases. Clinical impairment should not automatically rule out pseudoprogression, and each case requires thorough evaluation. High PD-L1 expression and greater tumor burden may be associated with PsP, but further studies are needed to confirm these findings.
引用
- Ibáñez-Juliá MJ, Bataller L, Cabello-Murgui FJ, et al. Clinical and radiological features of pseudoprogression in brain tumors treated with immune checkpoint inhibitors. J Neurooncol. 2025. PMID: 40426008. doi:10.1007/s11060-025-05091-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。